

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SUNSHINE LAKE PHARMA CO., LTD.

廣東東陽光藥業股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6887)

VOLUNTARY ANNOUNCEMENT
CORE PRODUCT OLORIGLIFLOZIN CAPSULES OBTAINED
MARKETING APPROVAL FROM NATIONAL MEDICAL PRODUCTS
ADMINISTRATION

This announcement is made by Sunshine Lake Pharma Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board of directors of the Company (the “**Board**”) is pleased to announce that a sodium glucose transporter 2 inhibitor (SGLT-2 inhibitor) and Class 1 innovative drug Olorigliflozin Capsules (Product Name: Dong Ze'an (東澤安); Strength: 20mg, 50mg) (the “**Product**”), independently researched and developed by the Group, has recently obtained marketing approval from China National Medical Products Administration (the “**NMPA**”) for use as monotherapy or in combination with metformin to improve glycemic control in adults with type 2 diabetes.

The registration approval of the Product is based on two Phase III clinical studies, which are multi-centered, randomized, double-blind and placebo-controlled. After 24 weeks of treatment, Olorigliflozin Capsules demonstrated a significant reduction in glycated hemoglobin (HbA1c) level compared to baseline statistically. The fasting blood glucose of the patients, in particular, their 2-hour postprandial glucose, showed significant improvement. Meanwhile, metabolic benefits, including body weight loss and systolic blood pressure reduction were also observed. The Product demonstrated remarkable efficacy in improving energy metabolism, in line with the contemporary trends in integrated diabetes management focusing on “blood glucose-body weight-blood pressure”. During clinical trials, the Product exhibited overall good tolerability, with no significant difference in the incidence of adverse events compared to the placebo groups.

As of today, diabetes has become the third most serious noncommunicable disease threatening human health worldwide, following cancer, cardiovascular and cerebrovascular diseases. According to the data from the International Diabetes Federation (IDF) Diabetes Atlas (11th edition), there were 148 million adults with diabetes in China aged 20–79, representing a prevalence rate of 13.79%, ranking first globally in the number of people with diabetes. Type 2 diabetes accounts for over 90%, and patients generally exhibit poor clinical medication compliance, with effective blood glucose control rate of merely 50.1%.

The Group has long been involved in the treatment of diabetes with a comprehensive product plan and a complete product line in place. The Group has independently researched and developed five insulin products, namely, Recombinant Human Insulin Injection, Insulin Glargine Injection, Insulin Aspart Injection, Insulin Aspart 30 Injection and Mixed Protamine Human Insulin Injection (30R), all of which have been approved for marketing. The aforementioned products demonstrate high consistency with the innovator drugs in key metrics, including efficacy, safety and quality control. Furthermore, all 5 products won the bid for National drugs centralized bulk procurement. The approval of this new product will further enrich the Group's diabetes product lines portfolio. The Group will leverage our established production system and marketing network to advance the commercialization of the Product. Meanwhile, clinical exploration in areas such as diabetes complications for the Product will be conducted to expand its range of indications, providing comprehensive treatment solutions for diabetes patients.

By order of the Board
Sunshine Lake Pharma Co., Ltd.
Dr. ZHANG Yingjun
Chairman

Dongguan, the PRC
16 January 2026

As at the date of this announcement, the executive directors are Dr. ZHANG Yingjun and Dr. LI Wenjia, the non-executive directors are Mr. ZHANG Yushuai, Mr. TANG Xinfu, Mr. ZHU Yingwei, Mr. ZENG Xuebo, Ms. DONG Xiaowei and Ms. WANG Lei, and the independent non-executive directors are Dr. LI Xintian, Dr. MA Dawei, Dr. YIN Hang Hubert, Dr. LIN Aimei and Dr. YE Tao.